The Early-Stage ACHIEVE Trial of Myotonic Dystrophy Continues to Show Success for DYNE-101.

Published Date: 26 May 2024

DYNE-101 showed dose-dependent splicing correction; at three months, the 5.4 mg/kg cohort's mean correction was 27%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Should the UK introduce targeted prostate cancer screening? The case for and against

5.

Germline Profiling May Improve Risk Stratification in t-MNs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot